Immutep

Second Funding

image Immutep S.A. announced today the closing in December of a second financing of €2.5 million ($3.25 million) taking the total amount raised externally by the Company to €5 million ($6.5 million). The proceeds will be used to take the Company’s lead product, IMP321, into Phase I/II clinical trials in the second quarter of 2005. IMP321 is a potent natural human T cell immunostimulatory factor designed to amplify the T cell immune response required to kill tumours and infected cells.

Published 01/2005 by admin@immutep.com
» Home
© 2002 Immutep, S.A.
Press Release
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
image Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer.
image Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
image Immutep S.A. announced today that the final results from its Phase ...
01/2010 - Interview Frederic Triebel with PharmaTelevision
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...